Market Size of Knock Out Mouse Model Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.37 Billion |
| Market Size (2029) | USD 1.79 Billion |
| CAGR (2024 - 2029) | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Knock Out Mouse Model Market Analysis
The Knock Out Mouse Model Market size is estimated at USD 1.37 billion in 2024, and is expected to reach USD 1.79 billion by 2029, growing at a CAGR of 5.20% during the forecast period (2024-2029).
During the COVID-19 pandemic, the knockout mouse model market was significantly impacted due to the wide usage of these models in COVID-19-related studies. Furthermore, the continued studies on COVID-19 in laboratories using the knockout mouse model are expected to continue growth over the coming period. For instance, as per the report published by eBioMedicine in December 2021, the suppression of NLRP3 inflammasome by genetic knockout and specific inhibitors in the mouse models consistently displayed its immune importance in COVID-19 disease progression. It showed the importance of the knockout mouse model in COVID-19 research, which is expected to boost the market over the coming years.
Factors driving the knockout mouse model market growth include the increasing development of novel and innovative drugs and medical devices, rising demand for personalized medicine, and advancements in gene editing tools. Additionally, the knockout mouse model market is expanding with increased R&D activities in pharmaceutical industries. For instance, in May 2021, Taysha Gene Therapies, Inc. published new preclinical data for TSHA-102 in Rett syndrome. TSHA-102 resulted in a statistically significant survival extension by 56% in 4-5-week-old knockout Rett mice with meaningful accumulated disease. In contrast, unregulated constructs did not extend survival significantly in the validated MECP2 knockout Rett mouse model. It shows the wide usage of knockout mouse models in various research studies.
For instance, as per the report published by Cyagen Biosciences in April 2021, the knockout mouse model is a crucial resource for drug development. To greatly increase pertinent insights into innovative diagnostic and therapeutic methods, heterozygous and homozygous knockout lines are frequently used in human disease research, such as for investigations of rare diseases and developmental disorders. These widespread applications of knockout mouse models in the pharmaceutical industry are expected to include significant growth in the market over the forecast period.
The strategic activities by the market players is expected to boost the market over the forecast period. For instance, in October 2022, Taconic Biosciences launched the FcResolv NOG portfolio, the super immunodeficient mouse model with a knockout of murine Fc gamma receptors (FcγRs). It is known to confound results in antibody-based therapy studies. Additionally, in August 2022, the University of California, Davis, awarded just over USD 12 million from the NIH under the third and final five-year phase of the Knockout Mouse Phenotyping Project, or KOMP2. This final phase of KOMP2 aims to produce and phenotype hundreds of knockout mouse models for genes with little to no known function to better understand the genetic bases for diseases in humans and animals.
However, alternatives to animal testing and regulations for the ethical use of animals are the major factors restraining the growth of the knockout mouse model market over the forecast period.
